AI Insight
Researchers identified sphingosine kinase 2 (SPHK2) as a critical driver of Group 3 medulloblastoma, the most lethal subtype of this pediatric brain cancer. SPHK2 suppresses the immune system's ability to fight tumors by inhibiting cytotoxic T-cells and NK cells while promoting immunosuppressive regulatory T-cells. Genetic deletion or pharmacological inhibition of SPHK2 using the drug Opaganib restored anti-tumor immunity and significantly extended survival in mouse models, with even greater benefits when combined with low-dose radiation therapy.
Why it matters
This study identifies a novel therapeutic target for Group 3 medulloblastoma, which currently lacks effective targeted treatments and causes severe long-term side effects with standard therapies. The combination of Opaganib and low-dose radiation offers a potentially safer and more effective treatment approach that could improve outcomes for children with this aggressive cancer.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Group 3 medulloblastomas (G3MB) carry the worst prognosis among medulloblastoma subtypes, yet molecularly targeted therapies remain elusive. Standard treatments cause severe long-term morbidity in survivors. Here, we identify tumor-derived sphingosine kinase 2 (SPHK2) as an essential driver of G3MB initiation and progression. SPHK2 exacerbates local immunosuppression by suppressing cytotoxic T-cell and NK-cell activity while promoting regulatory T-cell infiltration. Genetic or pharmacologic SPHK2 inhibition using Opaganib attenuates pro-survival tumor signaling and restores anti-tumor immunity, significantly improving survival in syngeneic G3MB mouse models. Combining Opaganib with fractionated low-dose radiation (f-LDRT) further enhances antigen presentation and reprograms tumor-associated myeloid cells toward an anti-tumor phenotype. This combination therapy markedly prolongs survival without inducing significant toxicity. Overall, our study establishes SPHK2 as a previously unrecognized therapeutic target and presents a safe, effective, microenvironment-reprogramming regimen for G3MB.